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Limbic-predominant age-related TDP-43
encephalopathy differs from frontotemporal
lobar degeneration
John L. Robinson,1,2,3 Sı́lvia Porta,1,2,3 Filip G. Garrett,4 Panpan Zhang,1,5
Sharon X. Xie,1,5 EunRan Suh,1,2,3 Vivianna M. Van Deerlin,1,2,3 Erin L. Abner,6,8
Gregory A. Jicha,7,8 Justin M. Barber,8 Virginia M-Y. Lee,1,2,3 Edward B. Lee1,2,3
John Q. Trojanowski1,2,3 and Peter T. Nelson4,8
TAR-DNA binding protein-43 (TDP-43) proteinopathy is seen in multiple brain diseases. A standardized terminology was recom-
mended recently for common age-related TDP-43 proteinopathy: limbic-predominant, age-related TDP-43 encephalopathy (LATE) and
the underlying neuropathological changes, LATE-NC. LATE-NC may be co-morbid with Alzheimer’s disease neuropathological
changes (ADNC). However, there currently are ill-defined diagnostic classification issues among LATE-NC, ADNC, and frontotempo-
ral lobar degeneration with TDP-43 (FTLD-TDP). A practical challenge is that different autopsy cohorts are composed of disparate
groups of research volunteers: hospital- and clinic-based cohorts are enriched for FTLD-TDP cases, whereas community-based cohorts
have more LATE-NC cases. Neuropathological methods also differ across laboratories. Here, we combined both cases and neuropa-
thologists’ diagnoses from two research centres—University of Pennsylvania and University of Kentucky. The study was designed to
compare neuropathological findings between FTLD-TDP and pathologically severe LATE-NC. First, cases were selected from the
University of Pennsylvania with pathological diagnoses of either FTLD-TDP (n = 33) or severe LATE-NC (mostly stage 3) with co-mor-
bid ADNC (n = 30). Sections from these University of Pennsylvania cases were cut from amygdala, anterior cingulate, superior/mid-
temporal, and middle frontal gyrus. These sections were stained for phospho-TDP-43 immunohistochemically and evaluated independ-
ently by two University of Kentucky neuropathologists blinded to case data. A simple set of criteria hypothesized to differentiate
FTLD-TDP from LATE-NC was generated based on density of TDP-43 immunoreactive neuronal cytoplasmic inclusions in the neocor-
tical regions. Criteria-based sensitivity and specificity of differentiating severe LATE-NC from FTLD-TDP cases with blind evaluation
was 90%. Another proposed neuropathological feature related to TDP-43 proteinopathy in aged individuals is ‘Alpha’ versus ‘Beta’
in amygdala. Alpha and Beta status was diagnosed by neuropathologists from both universities (n = 5 raters). There was poor inter-
rater reliability of Alpha/Beta classification (mean j = 0.31). We next tested a separate cohort of cases from University of Kentucky
with either FTLD-TDP (n = 8) or with relatively ‘pure’ severe LATE-NC (lacking intermediate or severe ADNC; n = 14). The simple
criteria were applied by neuropathologists blinded to the prior diagnoses at University of Pennsylvania. Again, the criteria for differenti-
ating LATE-NC from FTLD-TDP was effective, with sensitivity and specificity 90%. If more representative cases from each cohort
(including less severe TDP-43 proteinopathy) had been included, the overall accuracy for identifying LATE-NC was estimated at
498% for both cohorts. Also across both cohorts, cases with FTLD-TDP died younger than those with LATE-NC (P50.0001). We
conclude that in most cases, severe LATE-NC and FTLD-TDP can be differentiated by applying simple neuropathological criteria.
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Introduction
TAR-DNA binding protein-43 (TDP-43) proteinopathy is
characterized by aberrantly phosphorylated and/or mislocal-
ized TDP-43 protein. There is general agreement that mil-
lions of individuals worldwide are affected by age-related
TDP-43 proteinopathy (Nelson et al., 2019a). Disease-specif-
ic diagnoses are important because some future therapeutic
strategies may work for particular subsets of patients but
not necessarily for others. However, important questions re-
main about classification systems for these neurodegenera-
tive disorders.
TDP-43 proteinopathy was discovered as a pathological
biomarker among individuals with several seemingly differ-
ent neurological disorders including amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar degeneration
(FTLD-TDP), but a number of overlapping features includ-
ing TDP-43 proteinopathy suggest the diseases are related
pathogenetically (Neumann et al., 2006). A small percentage
of individuals on the ALS/FTLD clinical-pathological spec-
trum harbour mutations in the TDP-43 encoding gene,
TARDBP (Sreedharan et al., 2008; Van Deerlin et al.,
2008). However, outside of the ALS/FTLD spectrum, there
are many additional genetic and environmental factors that
drive TDP-43 proteinopathy with neurological impairment
(Chornenkyy et al., 2019).
By far the most prevalent known subset(s) of TDP-43 pro-
teinopathy occur in advanced old age; TDP-43 proteinop-
athy is observed in 30–50% of individuals who die beyond
85 years of age (Nelson et al., 2019a). In this context, the
TDP-43 proteinopathy is associated with substantial cogni-
tive impairment, especially in the cognitive domain of epi-
sodic memory (Nag et al., 2017; Robinson et al., 2018a).
Usually, affected individuals lack clinical features of fronto-
temporal dementia (FTD), e.g. aphasia and severe disinhib-
ition (Nelson et al., 2013, 2019a; Jung et al., 2014).
Multiple classification systems for TDP-43 proteinopathy
have been proposed. An international group of experts re-
cently conferred about common (41 in 10 lifetime risk) age-
related TDP-43 proteinopathy (Nelson et al., 2019a). New
terminology was recommended: limbic-predominant, age-
related TDP-43 encephalopathy (LATE) and its underlying
substrate of LATE neuropathological changes (LATE-NC).
LATE-NC may occur with or without co-morbid
Alzheimer’s disease neuropathological changes (ADNC).
However, it has been proposed that the suggested classifica-
tion of age-related TDP-43 proteinopathy as LATE-NC is
problematic (Josephs et al., 2019a), partly because of cur-
rently ill-defined diagnostic boundary zone issues pertaining
to ADNC and FTLD-TDP. Another proposed neuropatho-
logical feature related to TDP-43 proteinopathy in aged indi-
viduals is an ‘Alpha’ (similar to FTLD-TDP pathological
type A) versus ‘Beta’ (occurring in and/or near ADNC-type
tau tangle structures) pattern of TDP-43 immunoreactivity
in the amygdala (Josephs et al., 2019b).
This is a complex subject area. There are differences in epi-
demiological, genetic, and neuroimaging features when com-
paring LATE-NC with FTLD-TDP (Nelson et al., 2019a).
However, particular neuropathological features of LATE-NC
resemble those seen in FTLD-TDP type A (Aoki et al., 2015).
Furthermore, LATE-NC affects both the superior temporal
cortex and mid-frontal cortex in 8–20% of cases, prompting
speculation that LATE-NC represents a mild or early stage in
the development of FTLD-TDP pathology rather than a dis-
tinct clinical-pathological entity (Josephs et al., 2016). There
are shared elements of genetic risk between FTLD-TDP and
LATE-NC (Murray et al., 2014; Dickson et al., 2015; Nelson
et al., 2016), as there are between ADNC and LATE-NC and
between tauopathies and Parkinson disease (Robinson et al.,
2018b; Wennberg et al., 2018; Yang et al., 2018;
Chornenkyy et al., 2019). From a neuropathological stand-
point, ADNC, hippocampal sclerosis, and brain arterioloscle-
rosis are all relatively frequent in individuals with LATE-NC
(Amador-Ortiz et al., 2007; Neltner et al., 2014; Smith et al.,
2017). Unfortunately, LATE-NC and FTLD-TDP have not
been systematically compared, partly because research
cohorts that have many FTLD-TDP cases may lack ‘pure’
LATE-NC cases, and vice versa.
In the present study, we tested whether or not LATE-NC
and FTLD-TDP are neuropathologically differentiable. We
obtained cases from the Center for Neurodegenerative
Disease Research at the University of Pennsylvania (CNDR
at UPENN) and the University of Kentucky Alzheimer’s
Disease Center (UK-ADC). We found that the large majority
of LATE-NC and FTLD-TDP cases had differentiating
pathological features.
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Materials and methods
Case selection
Overall study design and workflow are depicted in Fig. 1. The a
priori goal was to select for evaluation in this study pathologic-
ally severe LATE-NC cases to compare with FTLD-TDP cases.
The reason for this was to focus on the cases that would be
most likely to represent diagnostic challenges relative to the dis-
tinction between LATE-NC and FTLD-TDP. A two-stage study
design was implemented wherein, first, cases originally diag-
nosed at UPENN were evaluated blindly by UK-ADC neuropa-
thologists. Next, cases originally diagnosed at UK-ADC were
evaluated blindly by UPENN neuropathologists. Age at death
was not factored into inclusion or exclusion criteria. In terms of
FTD clinical features, the behavioural variant of FTD (bvFTD)
is signalled by behavioural disinhibition, apathy, loss of em-
pathy, compulsive behaviours, and executive dysfunction
(Rascovsky et al., 2007), and can occur with or without motor
neuron disease characterized by weakness and spasticity (Strong
et al., 2017). Primary progressive aphasia (PPA) is a language
disorder with impairment of either naming and understanding
of words and objects (semantic variant of PPA), or slowing of
speech, or grammar difficulties and muteness (non-fluent/agram-
matic PPA) (Gorno-Tempini et al., 2011).
A series of FTLD-TDP and LATE cases was assembled from
patients who participated in the UPENN CNDR brain donation
program (Table 1) (Mackenzie et al., 2011; Toledo et al., 2014;
Lee et al., 2017). The FTLD-TDP cohort was a subset of 125
patients from the CNDR cohort with a primary neuropatho-
logical diagnosis of FTLD-TDP. Forty-four patients had a pri-
mary or secondary diagnosis of clinical frontotemporal
dementia, behavioural variant (bvFTD). Of these, 35 were well-
characterized research participants with additional clinical test-
ing [Mini-Mental State Examination (MMSE) and/or Boston
Naming scores], and 33 cases had available mid-frontal cortex,
superior temporal cortex, anterior cingulate and amygdala tis-
sue; these 33 cases were included. This cohort included FTLD-
TDP type A, B, C and E as diagnosed by neuropathologists at
Figure 1 Overall study design. Before grading the cases, hypothetical criteria were developed for differentiating LATE-NC
from FTLD-TDP. These criteria were based on two assumptions: (i) a pattern of TDP-43 immunohistochemical staining interpreted to repre-
sent FTLD-TDP types C, D, or E was indicative of FTLD-TDP, not compatible with LATE-NC; and (ii) if the density of TDP-43 immunoreactive
neuronal cytoplasmic inclusions (NCIs) was moderate or high in frontal cortex, it also was indicative of FTLD-TDP rather than LATE-NC. Next,
we followed a two-stage study design. The first cases series, from University of Pennsylvania (UPENN), consisted of n = 33 cases with FTLD-
TDP, and n = 30 cases with relatively severe LATE-NC, the large majority with co-morbid ADNC. Paraffin sections from amygdala, anterior
cingulate, superior and middle temporal gyrus, and middle frontal gyrus were selected for the study. The sections were stained for phospho-
TDP-43 at University of Kentucky (UKY) and TDP-43 pathology was evaluated by two UKY neuropathologists, applying the ad hoc criteria for
differential diagnosis of LATE-NC or FTLD-TDP. Next, a separate cohort from UKY was selected, comprising n = 8 cases with FTLD-TDP and
n = 14 cases with relatively severe LATE-NC, lacking co-morbid ADNC. These sections were immunostained for phospho-TDP-43 at UKY and
TDP-43 pathology was evaluated by two UPENN neuropathologists, applying the same ad hoc criteria for differential diagnosis of LATE-NC or
FTLD-TDP except also including ropy dystrophic neurites in the analyses. Ant Cingulate = anterior cingulate; DN = various types of TDP-43
immunoreactive dystrophic neurites; GFNI = granulofilamentous neuronal inclusions; NII = neuronal intranuclear inclusions; MFG = middle
frontal gyrus; SMTG = superior and middle temporal gyri; WM GCI = white matter glial cytoplasmic inclusions.
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UPENN (Mackenzie and Rademakers, 2007). There was a mix
of sporadic and genetic cases, and 19 were known to harbour
C9orf72, GRN, or TBK1 mutations. The LATE-NC cohort
from UPENN was a subset of 533 patients with a primary
neuropathological diagnosis of unremarkable adult brain, pri-
mary age-related tauopathy (PART), argyrophilic grain disease,
pathological ageing, predominantly cerebrovascular pathology,
or ADNC, and with final clinical diagnoses that included unim-
paired, cognitively impaired, vascular dementia, or Probable
Alzheimer’s disease. From this cohort, 205 patients had a neuro-
pathological diagnosis of LATE-NC. Each of these 205 cases
was assigned a TDP-43 proteinopathy severity stage (range 0–
6), similar to the staging scheme of Josephs et al. (2016), as well
as a LATE-NC stage (range 0–3) (Nelson et al., 2019a). The 30
LATE-NC cases with the highest TDP-43 severity stages and
available mid-frontal cortex, superior temporal cortex, anterior
cingulate and amygdala tissue were selected for inclusion into
the study (n = 30).
A separate series of FTLD-TDP and LATE-NC cases was
assembled from the UK-ADC biobank (Table 1). The FTLD-
TDP cohort included each non-tau FTD/FTLD case from the en-
tire UK-ADC Brain Bank (n = 8). Notably, whereas the large
majority of cases in the UK-ADC Brain Bank were recruited
from the community (with normal cognitive status at recruit-
ment) for extensive longitudinal follow-up, all of the FTLD-
TDP cases represented in the UK-ADC were recruited from an
associated memory disorders clinic. One of the FTLD-TDP cases
was found to harbour a VCP mutation (c.464G4A, p.R155H),
genotyped as part of the current study. The UK-ADC LATE-NC
series was selected to fulfil the following criteria: (i) documented
dementia (because we wanted to compare the LATE-NC cases
with FTLD-TDP cases which had substantial disease burden);
(ii) lacking ‘intermediate’ or ‘severe’ ADNC according to the
National Institute on Aging Alzheimer Association (NIA-AA)
consensus criteria (Montine et al., 2012); (iii) lacking other se-
vere pathology such as neocortical Lewy body pathology; and
(iv) they represent the most severe TDP-43 proteinopathy pos-
sible. Based on the above criteria, cases with brain tumours,
neocortical Lewy body disease, or a rare (e.g. prion) brain dis-
ease were excluded. There were 189 cases with retrospectively
diagnosed LATE-NC in the UK-ADC cohort. Of these, 46 had
low/minimal ADNC. However, some of these 46 cases had final
documented clinical states other than dementia (n = 21), sub-
stantial Lewy body pathology (n = 12), and/or met some other
exclusion criterion (e.g. brain cancer). A subset of the cases
were assessed for LATE-NC genetic risk alleles as described in
detail previously (Nelson et al., 2019c). For the present study,
among the cases with LATE-NC but lacking significant ADNC,
14 cases were selected for inclusion, all of which had docu-
mented dementia diagnosis. All LATE-NC cases were at least
Table 1 Cohort demographics from UPENN CNDR and UK-ADC
UPENN CNDR UK-ADC
FTLD-TDP LATE-NC FTLD-TDP LATE-NC
n 33 30 8 14
Age at death (mean ± SD) 66.6 ± 9.3 88.6 ± 6.4 62.9 ± 9.8 90.9 ± 8.5
Clinical diagnosis at last exama
No documented impairment 0 0 2 0
Mild cognitive impairment 0 3 0 0
Vascular dementia 0 1 0 2
Probable Alzheimer’s disease 2 26 0 12
bvFTD-FTLD 2 0 2 0
bvFTD-FTLD/MND 5 0 2 0
bvFTD-FTLD/PPA 5 0 2 0
Genetics
C9orf72 expansion 11 0 N/A N/A
GRN variant 7 0 N/A N/A
TBK1 variant 1 0 N/A N/A
VCP mutation 0 0 1 N/A
FTLD-TDP type
Type A or B 23 N/A 4 N/A
Type C 6 N/A 2 N/A
Type D 0 N/A 1 N/A
Type E 4 N/A 1 N/A
LATE-NC stage
Stage 0 N/A 0 N/A 0
Stage 1 N/A 0 N/A 0
Stage 2 N/A 2 N/A 9
Stage 3 N/A 28 N/A 5
Intermediate/high ADNCb 4 28 0 0
bvFTD = behavioural variant FTD; MND = motor neuron disease; N/A = not assessed; PPA = primary progressive aphasia.
aFor clinical diagnostic criteria and definitions, see ‘Materials and methods’ section.
bAccording to NIA-AA neuropathological criteria (66).
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LATE-NC stage 2, i.e. TDP-43 proteinopathy was observed in
the hippocampus (Nelson et al., 2019a). For the number of
cases in each cohort that were included and excluded for further
analyses, stratified by LATE-NC stage status, see Supplementary
Table 1.
Immunohistochemistry
Brain tissues were fixed in 10% formaldehyde, processed in par-
affin blocks, and sections were cut at 8-mm thickness.
Immunohistochemical staining for phospho-TDP-43 (1D3 clone,
1:500 dilution, purchased from EMD Millipore) was performed
as described previously (Smith et al., 2017; Gal et al., 2018).
Neuropathological evaluations
Individual TDP-43 proteinopathy subtype scores were assigned
on a 4-tier semi-quantitative scale (range 0–3) for eight individ-
ual subtypes of brain changes diagnosable using phospho-TDP-
43 immunohistochemistry. The TDP-43 neuropathological fea-
tures analysed included: (i) neuronal cytoplasmic inclusions; (ii)
neuronal intranuclear inclusions; (iii) glial cytoplasmic inclu-
sions; (iv) granulofilamentous neuronal cytoplasmic inclusions
(Lee et al., 2017); and (v) perivascular compact inclusions [com-
pact perivascular compact inclusions as described by Lin et al.,
2009)]. Various types of TDP-43-immunoreactive dystrophic
neurites were scored including ropy, long type C and punctate
dystrophic neurites (Fig. 2). The rubric for this semi-quantitative
operationalization was: no pathological phospho-TDP-43
immunoreactivity = 0; 1–2 structures per 40 magnification
high power microscope field (hpf) = 1; 3–15 structures/hpf = 2;
and 415 structures/hpf = 3. We also evaluated whether differ-
entiation of LATE-NC from FTLD-TDP could be improved by
assessing for the presence of type Beta inclusions in the
amygdala. The presence or absence of type Beta inclusions was
noted for the 63 cases from UPENN (Josephs et al., 2019b).
The overall FTLD-TDP subtype was assigned based on prior
published recommendations (Cairns et al., 2007; Lee et al.,
2017; Mackenzie and Neumann, 2017). Briefly, FTLD-TDP
subtyping was evaluated through examination of neocortical
sections stained for pTDP-43 (1D3 clone), using the morpho-
logical criteria described in detail in Supplementary Table 2. For
pathological assessment, each rater was blinded to the clinical
diagnosis, any other information about the case, and any other
pathological data or slides for review. Cases were analysed in a
randomized order with anonymized slide labels. For the
UPENN case series, pathology was independently assessed by
P.N. (UK-1) and F.G. (UK-2). For the UK-ADC cohort, path-
ology was independently assessed by S.P. (UP-1) and J.R. (UP-
2). Type Beta assignment was performed by F.G., P.N., J.R.,
S.P. and E.L. (UP-3).
Statistics
Statistical analyses used the R software, version 3.3.2. Ages at
death between FTLD-TDP and LATE were compared using
Welch’s t-test after running the Shapiro-Wilk test for checking
the normality assumption. Rater agreement for individual TDP-
43 morphologies between the UK-1 and UK-2 datasets were cal-
culated by weighted Cohen’s j. Type Beta correlations were cal-
culated by standard, non-weighted Cohen’s j, unsupervised.
TDP-43 histopathological severity scores for the FTLD-TDP
and LATE-NC cases were compared by Mann-Whitney-
Wilcoxon tests to determine P-values with the introduction of
false discovery rate (FDR) corrections for handling multiple
testing. Clustering analysis was performed with the k-means
clustering method for k = 2, 3 and 4. All statistical tests were
two-sided. Statistical significance was set at the 0.05 level.
Figure 2 Representative photomicrographs showing TDP-43 immunoreactive features in LATE-NC and FTLD-TDP. TDP-43
neuropathological features in FTLD-TDP type A/B (A–C) and LATE-NC (D–F) are similar in morphology but frequently differs by severity.
Dense neuronal cytoplasmic inclusions (NCIs, red arrows; B) and ropy dystrophic neurites (dystrophic neurites shown with green arrowheads;
C) are seen the superficial neocortical layers in FTLD-TDP type A middle frontal gyrus. LATE-NC middle frontal gyrus has milder pathology (E)
and punctate dystrophic neurites (F) can be seen in both FTLD-TDP and LATE-NC. Scale bars = 3 mm in A and D; 50 mm in B, C, and F; 100
mm in E.
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Data availability
The authors confirm that the data supporting the findings of
this study are available within the article, especially in the sup-
plementary tables.
Raw data were generated at the University of Kentucky and
the University of Pennsylvania. Although the large majority of
data are presented in the paper as stated above, any derived
data supporting the findings of this study are available from the
corresponding author (P.T.N.) on request.
Results
We tested whether LATE-NC could be pathologically distin-
guished from FTLD-TDP by the severity of cortical TDP-43
inclusions and/or the presence of type C–E pathology. We
also assessed if differentiating LATE-NC could be helped by
assessing for the presence of type Beta inclusions in the
amygdala. To test these hypotheses, we assembled a selec-
tion of FTLD-TDP cases and pathologically severe LATE-
NC cases (Table 1).
For the UPENN case series, in groupwise comparisons,
FTLD-TDP and LATE-NC cases differed by age of death
and clinical symptoms. The average age at death was sub-
stantially lower in the FTLD-TDP cases, (66.6± 9.3 years),
compared to the LATE-NC cases (88.6±6.4 years).
Clinically, the FTLD-TDP subjects usually presented with
bvFTD compared to a predominantly probable Alzheimer’s
disease diagnosis in the LATE-NC group. ADNC was lim-
ited in the FTLD-TDP group, with intermediate or high
ADNC rarely present (12%, n = 4/33). However, among the
LATE-NC group, the majority had an intermediate or high
ADNC (93%, n = 28/30). Genetically, 43% of the FTLD-
TDP cases were considered sporadic (n = 14/33), and the
C9orf72 expansion and GRN mutation carriers were the
most common genetic association among those with known
pathogenetic alleles, 33% and 21%, respectively.
The severity of eight TDP-43 pathology subtypes was
scored in the amygdala and three cortical areas for each case
from UPENN. Examples of some of these histopathologies
are depicted in Fig. 2. Scores were assigned for the severity
of typical neuronal cytoplasmic inclusions (Fig. 2B and E),
ropy dystrophic neurites (Fig. 2C), punctate dystrophic neu-
rites (Fig. 2F), compact perivascular inclusions (Lin et al.,
2009), and white matter glial cytoplasmic inclusions.
Morphologies associated with specific FTLD-TDP subtypes
included type C long dystrophic neurites, type D neuronal
intranuclear inclusions, and type E granulofilamentous neur-
onal cytoplasmic inclusions (Lee et al., 2017). See
Supplementary Table 2 for detailed description of how
FTLD-TDP types were operationalized. Finally, the presence
or absence of type Beta inclusions in the amygdala (Josephs
et al., 2019b) was noted for each case.
Assessing the UPENN cases, two UK-ADC neuropatholo-
gists, blinded to the original neuropathological diagnoses
and demographics of each case, independently assigned each
case a pathological diagnosis of either LATE-NC or FTLD-
TDP (Table 2). Only the four TDP-43 immunostained slides
were available to these neuropathologists. However, the
diagnostic accuracy of both neuropathologists in terms of
predicting the prior diagnoses was quite high. Specificity for
LATE-NC and FTLD-TDP was 91–94% and 80–97%, re-
spectively. Sensitivity for LATE-NC and FTLD-TDP was
similarly high at 80–97% and 91–94%, respectively.
To understand which subset of neuropathological TDP-43
features best distinguish LATE-NC from FTLD-TDP, we
asked if any of the scored TDP-43 proteinopathy subtypes
were reliably diagnosed between neuropathologists. FTLD-
TDP is a rare neurodegenerative disease (Knopman and
Roberts, 2011; Coyle-Gilchrist et al., 2016) and many of the
pathological morphologies assessed here—especially the
type-specific morphologies—are infrequently observed by
most practicing neuropathologist. Further, the experience of
each neuropathologist can influence the assessment of the se-
verity of each morphology. Here, one of the UK-ADC neu-
ropathologists was an attending neuropathologist (P.N.),
whereas the other was a neuropathology fellow in training
(F.G.). A weighted Cohen’s j-test measured the agreement
between the two UK-ADC neuropathologists’ scores for
each morphology. Ropy dystrophic neurites were the most
reliably scored (0.77), followed by granulofilamentous neur-
onal cytoplasmic inclusions (0.69), type C dystrophic neu-
rites (0.65) and typical neuronal cytoplasmic inclusions
(0.64). Less reliably scored between neuropathologists were
glial cytoplasmic inclusions (0.49), punctate dystrophic neu-
rites (0.45), neuronal intranuclear inclusions (0.36) and com-
pact perivascular compact inclusions (0.19) (Supplementary
Table 3). We emphasize that we used a relatively conserva-
tive approach for assessing reliability (e.g. scores of 2 and 3
would be considered disagreement), rather than a presence/
absence criteria. These results provided support for the se-
cond stage of the study where cases from the UK-ADC were
evaluated at UPENN, focusing on the neuronal cytoplasmic
inclusions and ropy dystrophic neurites.
Table 2 UPENN cases: diagnostic accuracy of UK-ADC neuropathologists
Pathologista UK-ADC blinded diagnosis UPENN LATE-NC diagnosis UPENN FTLD-TDP diagnosis Specificity (%) Sensitivity (%)
UK-1 LATE-NC (n = 32) 29 3 91 97
FTLD-TDP (n = 31) 1 30 97 91
UK-2 LATE-NC (n = 26) 24 2 94 80
FTLD-TDP (n = 37) 6 31 80 94
aUK-1 is an attending neuropathologist (P.N.); UK-2 is a neuropathology fellow in training (F.G.).
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Type Beta morphology, as defined previously (Josephs
et al., 2019b), was assessed as the presence or absence of the
pathology in the amygdala. Our a priori hypothesis was that
type Beta would be diagnosed in 50% of LATE-NC cases
and would be absent in FTLD-TDP cases (Josephs et al.,
2019b). Instead, type Beta was variably recorded in 50–
80% of LATE-NC cases, and in 18–33% of FTLD-TDP
cases (Supplementary Table 4). The same slides were then
evaluated blindly by three additional researchers from
UPENN. Type Beta was again variably observed in 30–67%
of LATE-NC and 6–19% of FTLD-TDP. Overall, there was
poor agreement between researchers with j ranging from
–0.02 to 0.59 (Supplementary Table 5). Applying an ad hoc
criterion for consensus (three or more of five raters agreed),
type Beta was observed in 57% of LATE-NC cases and
12% of FTLD-TDP cases. We conclude that type Beta
appears to be enriched in LATE-NC versus FTLD-TDP
cases, but low Cohen’s j makes it an unreliable indicator.
To understand if specific TDP-43 pathological features
distinguished FTLD-TDP from LATE-NC, we examined the
average pathological severity scores by brain region (Fig. 3).
The primary case-level data related to TDP-43 proteinop-
athy subtypes are provided in Supplementary Table 6. We
performed additional p-TDP-43 immunohistochemical stains
on the hippocampal formation (cornu ammonis, subiculum,
and entorhinal cortex) and these data are reported in
Supplementary Table 7. While both FTLD-TDP and LATE-
NC groups had similar burdens of pathology in the amyg-
dala (the sample was highly enriched for severe LATE-NC),
cortical pathology was typically more severe in FTLD-TDP
than in LATE-NC. Moderate to severe neuronal cytoplasmic
inclusions and ropy dystrophic neurites were observed in
cortical regions in FTLD-TDP and these were mostly rare to
mild in LATE-NC. In addition to neuronal cytoplasmic
inclusions and ropy dystrophic neurites, white matter glial
cytoplasmic inclusions, punctate dystrophic neurites and
neuronal intranuclear inclusions were also more severe in
FTLD-TDP than LATE-NC in the anterior cingulate and
mid-frontal gyri (P-values 4 0.0001). The FTLD-TDP type
E associated granulofilamentous neuronal cytoplasmic inclu-
sions and the FTLD-TDP type C dystrophic neurites affected
only a minority of cases, and were very rarely observed in
cortical areas in LATE-NC. Compact perivascular inclusions
were variably found across all regions and only in the amyg-
dala was different between FTLD-TDP and LATE-NC (P-
value 50.05), with the relevant caveat related to the modest
sample sizes.
To verify that our data support the existence of different
clusters of pathological features, we performed unsupervised
k-means cluster analysis for k = 2, 3, 4 using all eight sub-
types of TDP-43 proteinopathy features across four different
brain regions (Supplementary Tables 8 and 9). With k = 2,
one cluster had accuracy for LATE-NC of 79% while the
other cluster had accuracy for FTLD-TDP of 83%. With
k = 3, one cluster had a LATE-NC accuracy of 79% and the
two other clusters were primarily FTLD-TDP cases: a large
cluster with 83% accuracy and small cluster of n = 7 with
100% accuracy for FTLD-TDP which also contained all the
type E cases. With k = 4, a more accurate LATE-NC cluster
was defined with 97% accuracy and this accounted for the
majority of LATE-NC cases. The remaining clusters were
primarily FTLD-TDP cases: a large cluster with 83% accur-
acy, a small cluster of n = 7 with 100% accuracy for FTLD-
TDP and containing all the type E cases and a small cluster
of n = 6 containing all the type C cases with 100% accuracy
for FTLD-TDP. A priori, our hypothesis was that FTLD-
TDP types C–E neuropathological patterns would only be
seen in cases with FTLD-TDP, but not LATE-NC. The k = 4
clustering analysis supports the existence of FTLD-TDP type
C, type E, type A/B and LATE-NC pathological groups with
high specificity.
Since the presence of FTLD-TDP types C–E define
pathological features that allowed for the clear differenti-
ation of FTLD-TDP from LATE-NC, we next asked which
regional morphologies distinguished FTLD-TDP types A/B
from LATE-NC. Mann-Whitney-Wilcoxon analysis
revealed that neuronal cytoplasmic inclusions and ropy
dystrophic neurites in the anterior cingulate, superior tem-
poral and middle frontal cortices were more severe in
FTLD-TDP types A/B cases than LATE-NC cases (P-values
5 0.001, Table 3). Similar results were obtained as
expected if LATE-NC was compared to all FTLD-TDP
types A–E (Supplementary Table 10). In these same
regions, mild to moderate punctate dystrophic neurites,
mild neuronal intranuclear inclusions and a mild burden
of white matter glial cytoplasmic inclusions also were dif-
ferent comparing FTLD-TDP and LATE-NC cases (P-val-
ues 5 0.01). We conclude that the presence of moderate
to severe neuronal cytoplasmic inclusions and ropy dys-
trophic neurites in multiple cortical regions are sufficient
criteria to distinguish reliably between FTLD-TDP types A/
B and severe LATE-NC.
To test the hypothesis that either the presence of FTLD-
TDP type C–E pathology or a moderate to severe burden of
cortical pathology would distinguish FTLD-TDP versus
LATE-NC, we assembled an additional case series from the
UK-ADC biobank (Table 1). The a priori goal was to in-
clude all cases from this biobank that could be diagnostic
dilemmas between severe LATE-NC and FTLD-TDP. We
also wanted to assess cases where the TDP-43 proteinopathy
occurred without substantial ADNC. To accomplish these
goals, the convenience sample included LATE-NC cases that
had substantial TDP-43 proteinopathy, with documented
clinical dementia, but without intermediate or severe levels
of ADNC. The FTLD-TDP cohort included all of the FTLD-
TDP cases from the entire UK-ADC biobank (n = 8). All of
these cases were referred to the UK-ADC from a University
of Kentucky-affiliated dementia clinic, most presented clinic-
ally with bvFTD, and the average age at death was 62.9
years (±9.8 years standard deviation, SD). By contrast, the
LATE-NC group was derived from a community-based co-
hort, most were diagnosed clinically as probable Alzheimer’s
disease, and they were older at death (90.9 years ± 8.5 years
SD). As with the UPENN sample, there was minimal overlap
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Figure 3 Scores of TDP-43 proteinopathic features by brain region, stratified by diagnosis of LATE-NC or FTLD. Cortical path-
ology is more severe in FTLD-TDP (red) compared to LATE-NC cases (green). TDP-43 pathology was scored separately for individual morphol-
ogies for each case and region. The burden of TDP-43 pathology in amygdala was similar between severe LATE-NC and FTLD-TDP and was
typically characterized by the presence of neuronal cytoplasmic inclusions (NCI), ropy dystrophic neurites (DN) and punctate dystrophic
neurites. Cortical pathology in anterior cingulate, superior and middle temporal, and middle frontal gyrus was more limited in LATE-NC. In
FTLD-TDP cases, there was typically moderate to severe neuronal cytoplasmic inclusions and ropy dystrophic neurites, which were usually mild
to rare to LATE-NC, although these cases were selected to represent the more severe portion of the LATE-NC pathological spectrum. Box and
whisker plots show the median (solid line) and whiskers indicate variability outside the upper and lower quartiles (average of datasets from two
neuropathologists, UK-1 and UK-2). *P5 0.05, **P5 0.01, ***P5 0.001, ****P5 0.0001 Mann-Whitney-Wilcoxon analysis. DN = various types
of TDP-43 immunoreactive dystrophic neurites, including DN characteristic of FTLD type C (Type C DN), ropy DN and punctate DN; GFNI =
granulofilamentous neuronal inclusions; NII = neuronal intranuclear inclusion; PV = perivascular TDP-43 proteinopathy; WM GCI = white mat-
ter glial cytoplasmic inclusion.
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in the FTLD-TDP and LATE-NC cohorts’ age ranges
(Supplementary Fig 1).
For the four cases in the UPENN data set that were mis-
called by the University of Kentucky (UK-1) rater, three
were FTLD-TDP cases called LATE-NC, and one case was
the reverse. Notably, each of the FTLD-TDP cases mis-diag-
nosed as LATE-NC had a genetic mutation. Two were posi-
tive for C9orf72 expansion, one had GRN mutation. This
shows that genetic analysis would help to reduce the number
of misdiagnoses; further, C9orf72 cases can be accurately
diagnosed by adding p62 immunohistochemical stains
(Mackenzie et al., 2014). All four of the cases mis-diagnosed
were scored as type Alpha according to the consensus of the
five readers (Supplementary Table 7), which may indicate
that integrating Alpha/Beta assessment in the future could
help with challenging cases. We did not find evidence that
the hippocampal formation phosphorylated TDP-43 immu-
nohistochemical staining results provided additional helpful
information with the caveat that the number of cases with
misdiagnoses was only four (Supplementary Table 7).
After the brain tissues from the UK-ADC cohort were cut
and stained, two independent UPENN researchers, blinded
to each case’s demographics or any other information,
assigned each case a pathological diagnosis of LATE-NC or
FTLD-TDP using the simple ad hoc criteria (Table 4). For
this analysis, only anterior cingulate, temporal and mid-
frontal cortex slides were analysed. After assigning all
FTLD-TDP type C, D and E cases a FTLD-TDP diagnosis,
the remaining cases with moderate neuronal cytoplasmic
inclusions and ropy dystrophic neurites scores were
diagnosed as FTLD-TDP. These diagnostic criteria made by
UPENN readers on cases from the UK-ADC cohort were
quite accurate. Specificity for LATE-NC and FTLD-TDP
was 88–93% and 79–88%, respectively. Sensitivity for diag-
nosing LATE-NC and FTLD-TDP was similarly high at 88–
93% and 88%, respectively.
Based on the estimated sensitivity for correctly diagnosing
LATE-NC provided in Tables 2 and 4, we considered how
including all cases at our respective brain banks that were
LATE-NC may affect the results. Because moderate-to-high
TDP-43 proteinopathy in the middle temporal gyri is
required for diagnosis of FTLD-TDP, and given Stage 1 and
2 LATE-NC have no TDP-43 in the middle temporal gyri,
we assumed that no Stage 1 or Stage 2 cases would be mis-
classified as FLTD-TDP. Assuming that the sensitivity on the
included cases would be comparable to the excluded cases,
the overall sensitivity for identifying LATE-NC versus
FLTD-TDP was 99% for both UK-ADC and UPENN.
Thus, given the rather larger number of LATE-NC cases
that were Stage 1 or 2 relative to Stage 3, our sensitivity to
discriminate LATE-NC from FTLD-TDP would increase.
Among 189 UK-ADC cases stained for TDP-43 proteinop-
athy in the frontal cortex, 79 brains had pathological TDP-
43 immunoreactivity and 46 brains with TDP-43 proteinop-
athy lacked severe ADNC. Of these 46 TDP[ + ]ADNC[–]
individuals, one case showed substantial TDP-43 proteinop-
athy that was diagnosed as FTLD-TDP by both UPENN
readers. Detailed information on this subject is shown in
Fig. 4. Note that there were features of the clinical history
that were suggestive of ‘overlap’ with clinical FTD—
Table 3 FTLD-TDP type A/B versus LATE-NC pathological severity differences
TDP-43 pathological feature FTLD-TDP type A/B cases only versus LATE-NC comparison by pathological feature: P-values
Amygdala Anterior cingulate Superior temporal Middle frontal
Ropy DN 0.17 50.001 50.001 50.001
NCI 0.57 50.001 50.001 50.001
WM GCI 0.001 50.001 50.001 50.001
Punctate DN 0.03 50.001 0.003 50.001
NII 0.05 50.001 50.001 50.001
Compact PV 0.16 0.17 0.45 0.04
P-values for Mann-Whitney-Wilcoxon tests for comparison of the LATE-NC cases (n = 30) and the FTLD-TDP Type A/B cases (n = 24), i.e. FTLD-TDP types C–E cases were
excluded in this analysis. Shown are results from UPENN cases as read blind by UK-ADC neuropathologists. Compact PV = compact perivascular lesions as described by Lin et al.
(2009). DN = various types of TDP-43 immunoreactive dystrophic neurites; NCI = neuronal cytoplasmic inclusion; NII = neuronal intranuclear inclusion; WM GCI = white matter
glial cytoplasmic inclusion.
Table 4 UK-ADC cases: diagnostic accuracy of UPENN neuropathologists
Observer UPENN blinded diagnosis UK-ADC LATE-NC diagnosis UK-ADC FTLD-TDP diagnosis Specificity (%) Sensitivity (%)
UP-1 LATE-NC (n = 14) 13 1 88 93
FTLD-TDP (n = 8) 1 7 93 88
UP-2 LATE-NC (n = 12) 11 1 88 79
FTLD-TDP (n = 10) 3 7 79 88
None of the subjects in this table had intermediate or high Alzheimer’s disease neuropathological changes, all had dementia.
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language disturbance (although not frank progressive apha-
sia), disinhibition, and appetite problems. Still, the overall
clinical picture prior to death was considered to represent
probable Alzheimer’s disease dementia. Other findings
including radiographical and genetics results related to this
individual are described in Fig. 4 and its legend. This small
minority of cases (1% of all cases and 2.5% of cases with
LATE-NC in the UK-ADC cohort) demonstrated overlap be-
tween the features of LATE-NC and FTLD-TDP.
Discussion
TDP-43 proteinopathy was assessed blindly by multiple neu-
ropathologists, in order to compare pathological features in
severe LATE-NC with FTLD-TDP. Neuropathologists from
two institutions assessed over 300 slides each, including
cases with FTLD-TDP, severe LATE-NC with co-morbid
ADNC, and also severe LATE-NC lacking ADNC. In the
UPENN CNDR cohort (a dementia clinic-based sample), we
compared findings in FTLD-TDP to cases with severe
LATE-NC and co-morbid ADNC. From the UK-ADC co-
hort, we compared FTLD-TDP cases to severe LATE-NC
cases lacking substantial co-morbid ADNC. The UK-ADC
LATE-NC cases were recruited from a community-based
autopsy cohort with most cases followed from a baseline of
normal cognitive status. We found that the neuropathologic-
al features of LATE-NC and FTLD-TDP were not identical;
the density of TDP-43 proteinopathy in neocortical regions
was more severe in FTLD-TDP cases than in severe LATE-
Figure 4 Detailed information on a presumed LATE-NC research subject with an unusual clinical-pathological combination of
clinical features. Clinical-pathological features included Alzheimer’s disease- and FTD-associated signs and symptoms, and neuropathology that
was similar to FTLD-TDP type A. Changes in global cognitive status over the course of 20 years on study, operationalized by longitudinal MMSE
scores at 18 successive clinic visits, are presented in A. Mild cognitive impairment (MCI) was diagnosed at age 90 and a final probable Alzheimer’s
disease (AD) diagnosis was made at age 94, within a year of death. Although the overall clinical picture was compatible with Alzheimer’s disease,
FTD-like symptoms were noted (including disinhibition and disorders in appetite and language), particularly in the final 5 years of life
(Supplementary Table 11). A CT scan at age 90 when MCI was diagnosed (B) revealed frontal and temporal atrophy. In terms of genetic findings,
this subject’s APOE allele status was e2/e3, homozygous for the TMEM106B risk allele (rs1990622 status TT), homozygous for the ABCC9 risk al-
lele (rs704180 status AA), and homozygous for the non-risk GRN allele (rs5848 status CC). At autopsy, neuropathology (C) revealed a moderate
number of neuronal cytoplasmic inclusions (red arrows) and dystrophic neurites across multiple cortical areas including the middle frontal gyrus.
Scale bar = 50 mm. There was also hippocampal sclerosis pathology, but virtually no brain amyloid-b (not shown). Notably, whereas a quarter of
cases from this community-based cohort had LATE-NC but lacked severe ADNC, only 2/79 of the UK-ADC cases with TDP-43 pathology had
moderately severe frontal cortex TDP-43 proteinopathy (D).
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NC cases (with or without co-morbid ADNC). We gener-
ated criteria that would differentiate between FTLD-TDP
and LATE-NC with 90% confidence, even when the inclu-
sion criteria focus on advanced LATE-NC cases. Yet we also
found that a small group of subjects had pathological fea-
tures that did not discriminate between subjects with LATE-
type clinical features and FTD/FTLD. In evaluating cases
with amygdala TDP-43 proteinopathy, we found poor inter-
rater reliability between neuropathologists in applying the
Alpha/Beta schema.
Age-related TDP-43 proteinopathy is a fast-moving and
controversial research area (Josephs et al., 2019a; Nelson
et al., 2019b). If and when success is achieved in the domain
of therapeutic strategies, it may become all the more import-
ant to have useful criteria for differentiating disease entities.
Neuropathology is considered the gold standard of deter-
mining neurodegenerative disease presence and severity
(Jack et al., 2018). Among pathologists in general, autopsies
are performed taking into account at least some clinical in-
formation. However, in recent years, there has been an em-
phasis—in the area of neurodegenerative disease
pathological studies—on creating criteria for neuropatho-
logical diagnoses that would not require integration of clinic-
al information (Jack et al., 2018). The benefit of this
approach is that it acknowledges that a disease (as defined
by pathological features) can be present in a prodromic
state, as one does not need clinical manifestations to identify
that a disease process has begun (analogous, for example, to
prostate cancer in advanced ageing). The application of spe-
cific criteria for operationalizing the identification of disease
presence and severity also provides testable hypotheses for
clinical-pathological correlations.
Key methodological features of the present work included
a relatively open-ended study design given that multiple neu-
ropathologists and researchers from both institutions
reviewed each slide blindly and independently. All of the neu-
ropathologists were only able to review a limited subsample
of slides, without any information about clinical features of
the cases. These slides had been previously diagnosed, and
the question we sought to address was whether or not FTLD-
TDP and severe LATE-NC cases could be differentiated from
each other. If there had been extensive overlap between the
findings in FTLD-TDP and LATE-NC, that would have been
reported. For the sake of uniformity, the TDP-43 immunohis-
tochemical staining were performed using the 1D3 antibody,
which recognizes phospho-Ser409/Ser410 residues of TDP-43
(Neumann et al., 2009). This is the reagent that most (about
two-thirds of) American Alzheimer’s disease research centres
use for TDP-43 immunohistochemical evaluation (Katsumata
et al., 2018).
The clinical and pathological boundaries between LATE-
NC and FTLD-TDP have not been fully delineated, as was
discussed in the consensus working group report on
LATE-NC (Nelson et al., 2019a). However it was previously
shown that LATE-NC histopathology resembles that seen in
the FTLD-TDP type A (Aoki et al., 2015). Arguments for
commonalities between LATE-NC and FTLD-TDP include
the neuroimaging finding of frontal and temporal atrophy in
cases with autopsy-proven LATE-NC, less dramatic atrophy
overall than FTLD-TDP cases, but still in the same regions
(Kotrotsou et al., 2015; Nelson et al., 2019a). There are also
areas of overlap in terms of genetic risk factors, although
neurodegenerative disease genetic risk factors tend to be
pleiotropic and the genetic risk factors for LATE-NC and
FTLD-TDP are not identical (Chornenkyy et al., 2019).
In the present study, a large majority of LATE-NC cases
could be reliably differentiated from FTLD-TDP cases based
on evaluating several slides of brain sections immunostained
for phosphorylated TDP-43. We generated and applied sim-
ple diagnostic criteria: LATE-NC had lower densities of
TDP-43 immunoreactive neuronal cytoplasmic inclusions
and ropy dystrophic neurites in anterior cingulate and mid-
frontal cortical regions. Whereas in our test cases the rate of
correct diagnoses using this criteria was 90%, that number
could have been far higher if we had selected LATE-NC
cases blindly, since overall only 20% of cases with LATE-
NC in community-based cohorts have neocortical TDP-43
pathology (Keage et al., 2014; Nag et al., 2015). This is an
important point: in the UK-ADC and UPENN cohorts, well
over 95% of LATE-NC cases would probably be differenti-
ated from FTLD-TDP using our criteria. The biggest discrep-
ancies between FTLD-TDP and LATE-NC are in
epidemiology and clinical features. LATE-NC is far more
common and (as underscored in the present study) affects
older individuals, with differing clinical outcomes (Nelson
et al., 2019a).
Although neocortical involvement with TDP-43 pathology
in FTLD-TDP was significantly higher than in LATE-NC,
several individuals (one exceptional case is presented in
Fig. 4 in detail) had late-onset clinical features of
Alzheimer’s disease dementia, but had pathology that
appeared similar to FTLD-TDP. In these cases, there was a
substantial amount of TDP-43 neuronal cytoplasmic inclu-
sions in neocortex. We note that there exist similar cases at
the border zones for other neuropathological entities so that
individual neuropathologists might disagree as to the correct
diagnosis. For example, in chronic traumatic encephalop-
athy, other tauopathies, and, in other disease categories, un-
usual cases can constitute diagnostic challenges despite the
presence of improved diagnostic tools and criteria (Schneider
et al., 1997; Wakabayashi and Takahashi, 2004; Boeve
et al., 2013; Kovacs et al., 2018; Forrest et al., 2019;
Iverson et al., 2019; Malek-Ahmadi et al., 2019). It still is
theoretically possible that FTLD-TDP and LATE-NC truly
represent a unitary continuum, analogous to younger/rare-
and older/common-onset versions of ADNC. However, it is
notable that unlike Alzheimer’s disease, the condition that
affects older individuals (LATE-NC) usually has a different
clinical phenotype and a more distinct distribution of
pathology.
Synergistic mechanisms appear to affect both ADNC
and LATE-NC, because the two pathologies frequently co-
occur in aged brains (Josephs et al., 2008, 2019a; Nag
et al., 2017; Smith et al., 2017). However, this tendency
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needs to be critically assessed. Some ADNC is detectable
in 80% of all elderly individuals’ brains (with or without
LATE-NC or clinical dementia) (Braak et al., 2011), so the
common finding of ADNC with LATE-NC needs to be
judged in that context: even if the pathological features
were independent of each other, 80% of individuals with
LATE-NC would have co-morbid ADNC. Further, many
aged subjects with severe ADNC lack LATE-NC, which
indicates that ADNC does not lead inevitably to LATE-
NC. Conversely, as shown in the current study and else-
where (Nelson et al., 2011; Nag et al., 2015), LATE-NC
often occurs in the absence of co-morbid ADNC. It has
been suggested that TDP-43 proteinopathy in the context
of ADNC is merely an ‘added’ pathology, analogous to
Lewy body pathology in the amygdala (Josephs et al.,
2019a). However, the presence of LATE-NC in cases with
co-morbid ADNC is still highly worthy of diagnostic note
since ADNC with LATE-NC has a more severe clinical
phenotype than ADNC without LATE-NC (Nelson et al.,
2010; Robinson et al., 2013). Recent imaging studies also
imply that brains with ADNC and co-morbid LATE-NC
have more atrophic hippocampi than those with ADNC
alone (Dawe et al., 2011; Josephs et al., 2017; Sahoo
et al., 2018; Bejanin et al., 2019; Nelson et al., 2019a).
Here, importantly, we found similar accuracy in differenti-
ating FTLD-TDP from LATE-NC, with or without co-
morbid ADNC.
We also tried to replicate the finding of a diagnostically
helpful stratification of cases by the Alpha and Beta pattern
of TDP-43 proteinopathy (Josephs et al., 2019b). We
attempted to apply the diagnostic criteria that were pub-
lished, after discussing them together. Five different research-
ers judged the same panel of cases. The diagnostic inter-rater
reliability was low for distinguishing Alpha and Beta types
(Supplementary Table 3). Nor were these diagnostic cues
very helpful in differentiating between LATE-NC and
FTLD-TDP in the UPENN sample. While Beta type morph-
ology was described by consensus in 57% of LATE-NC ver-
sus 12% of FTLD-TDP, the diagnoses lacked practical
utility in the present study. Criteria for Alpha and Beta sub-
types of LATE-NC may in the future be sharpened to enable
better inter-rater reliability which is a prerequisite for any
diagnostic criterion.
This study had limitations and potential confounders. For
example, the presence of co-morbid pathologies in human
brains differs according to age, and also tends to change
according to the criteria applied in recruiting research volun-
teers. Further, the lifetime risk for FTLD-TDP is 1:1000
(Knopman and Roberts, 2011; Coyle-Gilchrist et al., 2016;
Nelson et al., 2019a), but FTLD-TDP may be highly
enriched in autopsy cohorts that draw from dementia clinics
or hospitals. By contrast, LATE-NC, including cases lacking
co-morbid ADNC, are more common in community-based
cohorts (Keage et al., 2014; Nag et al., 2017, 2018). Here
we included subjects derived from two institutions, repre-
senting one clinic-based cohort the second cohort that was
predominantly a community-based sample. However,
neither of these cohorts is ethnically diverse and more work
is required in more population-representative samples.
In addition, there were case selection biases in these con-
venience samples. The study design was biased to compare
FTLD-TDP and severe LATE-NC since the great majority of
cases with presumed incipient or moderately severe LATE-
NC were excluded. By contrast, cases more likely to have
overlapping neuropathological features, with neocortical
TDP-43 pathology and with frank dementia, were preferen-
tially included. It remains an open question how the neuro-
pathologies in the early and mild cognitive impairment
(MCI) stage of FTLD-TDP could be compared with LATE-
NC. Unfortunately, we did not have enough cases to assess
this. We were able to provide preliminary criteria to differen-
tiate between FTLD-TDP and LATE-NC, even in LATE-NC
brains enriched for relatively severe neocortical TDP-43
pathology, all without foreknowledge of clinical symptoms,
age of onset or genetic information. Future criteria could be
more specific by integrating genetic data, and also perhaps
other information such as non-phosphorylated TDP-43 pro-
teinopathy and pathological lesions in other brain regions
(Hunter et al., 2020).
The tendency is remarkable for TDP-43 proteinopathy in
LATE-NC to not progress—even in individuals with
advanced old age that lack co-morbid ADNC—to severe lev-
els of frontal and cingulate cortical involvement. It is tempt-
ing to speculate that there is a parallel with PART, in which
the anatomical progression of tau tangles, in the absence of
amyloid-b plaques, does not progress beyond Braak neuro-
fibrillary tangle stage IV (Nelson et al., 2009; Crary et al.,
2014). The observed phenomena in LATE-NC and FTLD-
TDP may indicate that an additive pathogenetic mechanism
or factor is present in FTLD-TDP that is lacking in LATE-
NC. More generally, the observations in LATE-NC under-
score that individual neurodegenerative diseases tend to have
distinct clinical and pathological progression trajectories
over time and they do not necessarily have the same disease-
defining clinical or pathological end point.
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